<DOC>
	<DOCNO>NCT00006994</DOCNO>
	<brief_summary>RATIONALE : Glutamine may effective decrease side effect , inflammation mouth throat , cause radiation therapy . The effectiveness glutamine mucositis yet know . PURPOSE : Randomized phase III trial determine effectiveness glutamine treat patient develop mucositis follow radiation therapy newly diagnose cancer mouth throat .</brief_summary>
	<brief_title>S9908 : Glutamine Treating Mucositis Caused Radiation Therapy Patients With Newly Diagnosed Cancer Mouth Throat</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy L-glutamine v placebo , term maximum mucositis toxic effect worst report mouth pain high-dose radiotherapy , patient newly diagnose , previously untreated squamous cell cancer oral cavity oropharynx . - Compare duration severe mucositis patient treat regimen . - Compare radiotherapy delay patient treat regimen . - Compare weight loss patient treat regimen . - Compare toxic effect two regimen patient . - Compare patient-reported mouth pain success rate patient treat regimen . - Determine compliance patient treat drug regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord concurrent cisplatin carboplatin ( yes v ) , concurrent fluorouracil ( yes v ) , presence feeding tube ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Beginning 4 7 day prior radiotherapy , patient receive oral L-glutamine 3 time daily 60-80 day . Patients receive concurrent high-dose radiotherapy approximately 6 week . - Arm II : Patients receive oral placebo high-dose radiotherapy arm I . In arm , treatment continue absence unacceptable toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A total 158 patient ( 79 per treatment arm ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose , previously untreated squamous cell cancer oral cavity oropharynx ( T1T4 , N , M0 ) Must schedule receive highdose radiotherapy Not concurrently receive plan receive treatment Southwest Oncology Group protocol PATIENT CHARACTERISTICS : Age : 18 90 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I II cancer currently complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Concurrent cisplatin , carboplatin , fluorouracil allow No concurrent chemotherapy study least 3 week study radiotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify Other : No concurrent amifostine 2 week study radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>oral complication radiation therapy</keyword>
	<keyword>pain</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>